Analysis of pro-inflammatory and resolutive parameters in patients with polycystic ovarian syndrome (PCOS)

Phase 1

• Conditions: E28.2; Polycystic ovarian syndrome

• Registration Number: DRKS00023242
• Lead Sponsor: Chemogroup

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-10-22
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Female
• Target Recruitment: 20

Inclusion Criteria

1. Female patients, age = 18 and = 45 years old
2. PCO Syndrome according to the Rotterdam criteria
3. Written informed consent

Exclusion Criteria

1. Current BMI <20 kg/m2
2. Patients with severe acute or chronic diseases (e.g. pancreatitis, hypertriglyceridemia, liver disease, benign or malignant liver tumour, malignant sex hormone-dependent diseases of genitals or breasts).
3. Migraines
4. Intake of herbal medicines that induce microsomal enzymes, in particular cytochrome P450 enzyme, e.g. phenytoin, phenobarbital, primidone, bosentan, carbamazepine, rifampicin, topiramate, felbamate, griseofulvin, some HIV protease inhibitors (e.g. ritonavir) and non-nucleoside reverse transcriptase inhibitors (e.g. efavirenz) and preparations of Aaron.
5. History of cardiovascular events
6. Advanced hypertension or Diabetes
7. Presence or known Risk of venous or arterial thromboembolism
8. Undiagnosed abnormal vaginal bleeding
9. Use of medical products which contain Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir during two weeks before the start of the study
10. Pregnancy and lactation throughout the study period
11. Patients who are postmenopausal

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Auswertung der inflammatorischen und resolutiven Plasma und Serum Parameter bei PCOs Patientinnen.

Secondary Outcome Measures

Name	Time	Method
ot applicable.